{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:15:34Z","timestamp":1777497334711,"version":"3.51.4"},"reference-count":32,"publisher":"China Science Publishing & Media Ltd.","content-domain":{"domain":["engine.scichina.com"],"crossmark-restriction":false},"short-container-title":["ABBS"],"published-print":{"date-parts":[[2024,5,1]]},"DOI":"10.3724\/abbs.2024058","type":"journal-article","created":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T06:38:05Z","timestamp":1717483085000},"update-policy":"https:\/\/doi.org\/10.1360\/scp-crossmark-policy-page","source":"Crossref","is-referenced-by-count":4,"title":["COL5A2 drives regorafenib resistance-induced metastatic                     phenotype via reducing LIFR expression in hepatocellular carcinoma"],"prefix":"10.3724","author":[{"given":"Shaoqin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuezhen","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengdan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yahan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenda","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jichuang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2026","published-online":{"date-parts":[[2024,5,31]]},"reference":[{"key":"CITATION1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"Sung H","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence                         and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71: 209-249.","journal-title":"CA Cancer J Clin"},{"key":"CITATION2","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s43018-022-00357-2","volume":"3","author":"Llovet JM","year":"2022","unstructured":"Llovet JM, Pinyol R, Kelley RK, El-Khoueiry A, Reeves HL, Wang XW, Gores GJ. Molecular pathogenesis and systemic therapies for hepatocellular                         carcinoma. Nat Cancer, 2022, 3: 386-401.","journal-title":"Nat Cancer"},{"key":"CITATION3","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","volume":"19","author":"Llovet JM","year":"2022","unstructured":"Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, Pikarsky E. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin                             Oncol, 2022, 19: 151-172.","journal-title":"Nat Rev Clin                             Oncol"},{"key":"CITATION4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.canlet.2018.12.010","volume":"444","author":"Wang J","year":"2019","unstructured":"Wang J, Zhang N, Han Q, Lu W, Wang L, Yang D, Zheng M. Pin1 inhibition reverses the acquired resistance of human                         hepatocellular carcinoma cells to regorafenib via the Gli1\/Snail\/E-cadherin                         pathway. Cancer Lett, 2019, 444: 82-93.","journal-title":"Cancer Lett"},{"key":"CITATION5","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1186\/s12967-019-2058-1","volume":"17","author":"Xu S","year":"2019","unstructured":"Xu S, Xu H, Wang W, Li S, Li H, Li T, Zhang W. The role of collagen in cancer: from bench to bedside. J Transl Med, 2019, 17:","journal-title":"J Transl Med"},{"key":"CITATION6","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.2147\/OTT.S288422","volume":"14","author":"Wang J","year":"2021","unstructured":"Wang J, Jiang YH, Yang PY, Liu F. Increased collagen type V \u03b12 (COL5A2) in colorectal cancer is                         associated with poor prognosis and tumor progression. Onco Targets Ther, 2021, 14: 2991-3002.","journal-title":"Onco Targets Ther"},{"key":"CITATION7","doi-asserted-by":"publisher","first-page":"BSR20204293","DOI":"10.1042\/BSR20204293","volume":"41","author":"Tan Y","year":"2021","unstructured":"Tan Y, Chen Q, Xing Y, Zhang C, Pan S, An W, Xu H. High expression of COL5A2, a member of COL5 family, indicates the                         poor survival and facilitates cell migration in gastric cancer. Biosci Rep, 2021, 41:","journal-title":"Biosci Rep"},{"key":"CITATION8","doi-asserted-by":"publisher","first-page":"583083","DOI":"10.3389\/fonc.2021.583083","volume":"11","author":"Ren X","year":"2021","unstructured":"Ren X, Chen X, Fang K, Zhang X, Wei X, Zhang T, Li G. COL5A2 promotes proliferation and invasion in prostate cancer and                         is one of seven gleason-related genes that predict recurrence-free survival. Front Oncol, 2021, 11:","journal-title":"Front Oncol"},{"key":"CITATION9","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3389\/fonc.2018.00659","volume":"8","author":"Meng XY","year":"2018","unstructured":"Meng XY, Shi MJ, Zeng ZH, Chen C, Liu TZ, Wu QJ, Li S. The role of COL5A2 in patients with muscle-invasive bladder                         cancer: a bioinformatics analysis of public datasets involving 787 subjects                         and 29 cell lines. Front Oncol, 2018, 8:","journal-title":"Front Oncol"},{"key":"CITATION10","doi-asserted-by":"publisher","first-page":"813809","DOI":"10.3389\/fonc.2022.813809","volume":"12","author":"Han YL","year":"2022","unstructured":"Han YL, Luo D, Habaxi K, Tayierjiang J, Zhao W, Wang W, Aikebaier W. COL5A2 inhibits the TGF-\u03b2 and Wnt\/\u03b2-catenin signaling pathways to                         inhibit the invasion and metastasis of osteosarcoma. Front Oncol, 2022, 12:","journal-title":"Front Oncol"},{"key":"CITATION11","doi-asserted-by":"publisher","first-page":"e24561","DOI":"10.1097\/MD.0000000000024561","volume":"100","author":"Ding YL","year":"2021","unstructured":"Ding YL, Sun SF, Zhao GL. COL5A2 as a potential clinical biomarker for gastric cancer and                         renal metastasis. Medicine, 2021, 100:","journal-title":"Medicine"},{"key":"CITATION12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10549-012-2123-4","volume":"135","author":"Vargas AC","year":"2012","unstructured":"Vargas AC, Reed AEMC, Waddell N, Lane A, Reid LE, Smart CE, Cocciardi S. Gene expression profiling of tumour epithelial and stromal                         compartments during breast cancer progression. Breast Cancer                             Res Treat, 2012, 135: 153-165.","journal-title":"Breast Cancer                             Res Treat"},{"key":"CITATION13","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1158\/1535-7163.MCT-20-0244","volume":"20","author":"Kohrt SE","year":"2021","unstructured":"Kohrt SE, Awadallah WN, Phillips Iii RA, Case TC, Jin R, Nanda JS, Yu X. Identification of genes required for enzalutamide resistance in                         castration-resistant prostate cancer cells in vitro. Mol Cancer                             Ther, 2021, 20: 398-409.","journal-title":"Mol Cancer                             Ther"},{"key":"CITATION14","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1182\/blood.V86.4.1243.bloodjournal8641243","volume":"86","author":"Kishimoto T","year":"1995","unstructured":"Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp130. Blood, 1995, 86: 1243-1254.","journal-title":"Blood"},{"key":"CITATION15","doi-asserted-by":"publisher","first-page":"188737","DOI":"10.1016\/j.bbcan.2022.188737","volume":"1877","author":"Halder S","year":"2022","unstructured":"Halder S, Parte S, Kshirsagar P, Muniyan S, Nair HB, Batra SK, Seshacharyulu P. The Pleiotropic role, functions and targeted therapies of                         LIF\/LIFR axis in cancer: old spectacles with new insights. Biochim                             Biophys Acta Rev Cancer, 2022, 1877:","journal-title":"Biochim                             Biophys Acta Rev Cancer"},{"key":"CITATION16","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.canlet.2009.08.013","volume":"289","author":"Okamura Y","year":"2010","unstructured":"Okamura Y, Nomoto S, Kanda M, Li Q, Nishikawa Y, Sugimoto H, Kanazumi N. Leukemia inhibitory factor receptor (LIFR) is detected as a novel                         suppressor gene of hepatocellular carcinoma using double-combination array. Cancer Lett, 2010, 289: 170-177.","journal-title":"Cancer Lett"},{"key":"CITATION17","doi-asserted-by":"publisher","first-page":"6989","DOI":"10.18632\/oncotarget.3136","volume":"6","author":"Luo Q","year":"2015","unstructured":"Luo Q, Zhang Y, Wang N, Jin G, Jin H, Gu D, Tao X. Leukemia inhibitory factor receptor is a novel immunomarker in                         distinction of well-differentiated HCC from dysplastic nodules. Oncotarget, 2015, 6: 6989-6999.","journal-title":"Oncotarget"},{"key":"CITATION18","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1093\/carcin\/bgv108","volume":"36","author":"Luo Q","year":"2015","unstructured":"Luo Q, Wang C, Jin G, Gu D, Wang N, Song J, Jin H. LIFR functions as a metastasis suppressor in hepatocellular                         carcinoma by negatively regulating phosphoinositide 3-kinase\/AKT pathway. Carcinogenesis, 2015, 36: 1201-1212.","journal-title":"Carcinogenesis"},{"key":"CITATION19","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1038\/s41467-021-27452-9","volume":"12","author":"Yao F","year":"2021","unstructured":"Yao F, Deng Y, Zhao Y, Mei Y, Zhang Y, Liu X, Martinez C. A targetable LIFR-NF-\u03baB-LCN2 axis controls liver tumorigenesis                         and vulnerability to ferroptosis. Nat Commun, 2021, 12:","journal-title":"Nat Commun"},{"key":"CITATION20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/mc.23279","volume":"60","author":"Zhang N","year":"2021","unstructured":"Zhang N, Zhang S, Wu W, Lu W, Jiang M, Zheng N, Huang J. Regorafenib inhibits migration, invasion, and vasculogenic                         mimicry of hepatocellular carcinoma via targeting ID1\u2010mediated EMT. Mol Carcinogenesis, 2021, 60: 151-163.","journal-title":"Mol Carcinogenesis"},{"key":"CITATION21","doi-asserted-by":"publisher","first-page":"105507","DOI":"10.1016\/j.phrs.2021.105507","volume":"166","author":"Zheng N","year":"2021","unstructured":"Zheng N, Zhang S, Wu W, Zhang N, Wang J. Regulatory mechanisms and therapeutic targeting of vasculogenic                         mimicry in hepatocellular carcinoma. Pharmacol Res, 2021, 166:","journal-title":"Pharmacol Res"},{"key":"CITATION22","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/mc.23402","volume":"61","author":"Yin H","year":"2022","unstructured":"Yin H, Wang H, Wang M, Yan Y, Dong Q, Li Q, Liu Y. CircTCF25 serves as a sponge for miR\u2010206 to support                         proliferation, migration, and invasion of glioma via the Jak2\/p\u2010Stat3\/CypB                         axis. Mol Carcinogenesis, 2022, 61: 558-571.","journal-title":"Mol Carcinogenesis"},{"key":"CITATION23","doi-asserted-by":"publisher","first-page":"6529","DOI":"10.1080\/21655979.2021.1973876","volume":"12","author":"Chen J","year":"2021","unstructured":"Chen J, Zhou L, Yang J, Xie H, Liu L, Li Y. Knockdown of STK39 suppressed cell proliferation, migration, and                         invasion in hepatocellular carcinoma by repressing the phosphorylation of                         mitogen-activated protein kinase p38. Bioengineered, 2021, 12: 6529-6537.","journal-title":"Bioengineered"},{"key":"CITATION24","doi-asserted-by":"publisher","first-page":"7782","DOI":"10.3390\/ijms23147782","volume":"23","author":"Wuputra K","year":"2022","unstructured":"Wuputra K, Hsiao PJ, Chang WT, Wu PH, Chen LA, Huang JW, Su WL. FOXM1-CD44 signaling is critical for the acquisition of                         regorafenib resistance in human liver cancer cells. Int J Mol Sci, 2022, 23:","journal-title":"Int J Mol Sci"},{"key":"CITATION25","doi-asserted-by":"publisher","first-page":"639779","DOI":"10.3389\/fcell.2021.639779","volume":"9","author":"Karabicici M","year":"2021","unstructured":"Karabicici M, Azbazdar Y, Ozhan G, Senturk S, Firtina Karagonlar Z, Erdal E. Changes in wnt and TGF-\u03b2 signaling mediate the development of                         regorafenib resistance in hepatocellular carcinoma cell line HuH7. Front Cell Dev                             Biol, 2021, 9:","journal-title":"Front Cell Dev                             Biol"},{"key":"CITATION26","doi-asserted-by":"publisher","first-page":"4681","DOI":"10.1038\/s41467-019-12606-7","volume":"10","author":"Wei L","year":"2019","unstructured":"Wei L, Lee D, Law CT, Zhang MS, Shen J, Chin DWC, Zhang A. Genome-wide CRISPR\/Cas9 library screening identified PHGDH as a                         critical driver for sorafenib resistance in HCC. Nat Commun, 2019, 10:","journal-title":"Nat Commun"},{"key":"CITATION27","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jhep.2020.11.008","volume":"74","author":"Arechederra M","year":"2021","unstructured":"Arechederra M, Bazai SK, Abdouni A, Sequera C, Mead TJ, Richelme S, Daian F. ADAMTSL5 is an epigenetically activated gene underlying                         tumorigenesis and drug resistance in hepatocellular carcinoma. J Hepatol, 2021, 74: 893-906.","journal-title":"J Hepatol"},{"key":"CITATION28","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.7150\/jca.26382","volume":"9","author":"Chen H","year":"2018","unstructured":"Chen H, Liu W, Zhong L, Liao D, Zhang R, Kang T, Wu Y. NKX2-2 suppresses osteosarcoma metastasis and proliferation by                         downregulating multiple target genes. J Cancer, 2018, 9: 3067-3077.","journal-title":"J Cancer"},{"key":"CITATION29","doi-asserted-by":"publisher","first-page":"20220593","DOI":"10.1515\/med-2022-0593","volume":"18","author":"Jin Y","year":"2023","unstructured":"Jin Y, Song X, Sun X, Ding Y. Up-regulation of collagen type V alpha 2 (COL5A2)                         promotes malignant phenotypes in gastric cancer cell via inducing                         epithelial\u2013mesenchymal transition (EMT). Open Med, 2023, 18:","journal-title":"Open Med"},{"key":"CITATION30","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2147\/OTT.S283026","volume":"14","author":"Gu Y","year":"2021","unstructured":"Gu Y, Wu F, Wang H, Chang J, Wang Y, Li X. Circular RNA circARPP21 acts as a sponge of miR-543 to suppress                         hepatocellular carcinoma by regulating LIFR. Onco Targets Ther, 2021, 14: 879-890.","journal-title":"Onco Targets Ther"},{"key":"CITATION31","doi-asserted-by":"publisher","first-page":"111677","DOI":"10.1016\/j.mrfmmm.2019.111677","volume":"816-818","author":"Real SAS","year":"2019","unstructured":"Real SAS, Parveen F, Rehman AU, Shaik R, Deo SVS, Husain SA. Mutation, methylation and expression analysis of LIFR gene in                         indian breast cancer patients. Mutat Res                             Fundamental Mol Mech Mutagenesis, 2019, 816-818:","journal-title":"Mutat Res                             Fundamental Mol Mech Mutagenesis"},{"key":"CITATION32","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12935-021-01982-0","volume":"21","author":"Yin W","year":"2021","unstructured":"Yin W, Zhu H, Tan J, Xin Z, Zhou Q, Cao Y, Wu Z. Identification of collagen genes related to immune infiltration                         and epithelial-mesenchymal transition in glioma. Cancer Cell Int, 2021, 21:","journal-title":"Cancer Cell Int"}],"container-title":["Acta Biochimica et Biophysica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/engine.scichina.com\/doi\/pdf\/3771C751B0B84CC2BA501CDF31E6A2F4","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/engine.scichina.com\/doi\/10.3724\/abbs.2024058","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/engine.scichina.com\/doi\/pdf\/3771C751B0B84CC2BA501CDF31E6A2F4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T06:38:07Z","timestamp":1717483087000},"score":1,"resource":{"primary":{"URL":"https:\/\/engine.scichina.com\/doi\/10.3724\/abbs.2024058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,1]]},"references-count":32,"URL":"https:\/\/doi.org\/10.3724\/abbs.2024058","relation":{},"ISSN":["1672-9145"],"issn-type":[{"value":"1672-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,1]]}}}